Pharmaceutical products

Tender description

Invitation to offer for NHS National Pharmaceuticals Transition 2019_1 Offer reference number: CM/PHG/17/5547 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 34 months. Potential periods of call-offs under the framework agreement: LSNE: 1.10.2019 to 30.4.2020 (7 months) CESW: 1.10.2019 to 30.9.2020 (12 months) NWLN: 1.10.2019 to 28.2.2021 (17 months) Awarded product list Bortezomib, arsenic, darunavir, atazanavir, ritonavir, miglustat, gefitinib, carglumic acid, clofaribine, ganciclovir, aprepitant, dexmedetomidine, solifenacin, atomoxetine, atovaquone, metaraminol and olopatadine. NHS National Pharmaceuticals Transition 2019_1 Offer reference number: CM/PHG/17/5547 Period of framework agreement: The total maximum Duration of the framework agreement to be no more than 34 months. Potential periods of call-offs under the framework agreement: LSNE: 1.10.2019 to 30.4.2020 (7 months) CESW: 1.10.2019 to 30.9.2020 (12 months) NWLN: 1.10.2019 to 28.2.2021 (17 months) NHS National Pharmaceuticals Transition 2019_1 Offer reference number: CM/PHG/17/5547 Period of framework agreement: The total maximum Duration of the framework agreement to be no more than 34 months Potential periods of call-offs under the framework agreement: LSNE: 1.10.2019 to 30.4.2020 (7 months) CESW: 1.10.2019 to 30.9.2020 (12 months) NWLN: 1.10.2019 to 28.2.2021 (17 months) NHS National Pharmaceuticals Transition 2019_1 Offer reference number: CM/PHG/17/5547 Period of framework agreement: The total maximum Duration of the framework agreement to be no more than 34 months Potential periods of call-offs under the framework agreement: LSNE: 1.10.2019 to 30.4.2020 (7 months) CESW: 1.10.2019 to 30.9.2020 (12 months) NWLN: 1.10.2019 to 28.2.2021 (17 months)